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Allosteric modulation of glycine receptors
Abstract
Inhibitory (or strychnine-sensitive) glycine receptors (GlyRs) are anion-selective transmitter-gated ion
channels of the cys-loop superfamily, which includes among others also the inhibitory γ-aminobutyric
acid receptors (GABA(A) receptors). While GABA mediates fast inhibitory neurotransmission
throughout the CNS, the action of glycine as a fast inhibitory neurotransmitter is more restricted. This
probably explains why GABA(A) receptors constitute a group of extremely successful drug targets in
the treatment of a wide variety of CNS diseases, including anxiety, sleep disorders, and epilepsy, while
drugs specifically targeting glycine receptors are virtually lacking. However, the spatially more
restricted distribution of glycinergic inhibition may be advantageous in situations when a more localized
enhancement of inhibition is sought. Inhibitory GlyRs are particularly relevant for the control of
excitability in the mammalian spinal cord, brain stem, and a few selected brain areas, such as the
cerebellum and the retina. At these sites, GlyRs regulate important physiological functions, including
respiratory rhythms, motor control, muscle tone and sensory as well as pain processing. In the
hippocampus, RNA-edited high affinity extrasynaptic GlyRs may contribute to the pathology of
temporal lobe epilepsy. Although specific modulators have not yet been identified, GlyRs still possess
sites for allosteric modulation by a number of structurally diverse molecules, including alcohols,
neurosteroids, cannabinoids, tropeines, general anaesthetics, certain neurotransmitters and cations. This
review summarizes the present knowledge about this modulation and the molecular bases of the
interactions involved.
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Summary 
Inhibitory (or strychnine-sensitive) glycine receptors (GlyRs) are anion-selective transmitter-
gated ion channels of the cys-loop superfamily, which includes among others also the 
inhibitory γ-aminobutyric acid receptors (GABAA receptors). While GABA mediates fast 
inhibitory neurotransmission throughout the CNS, the action of glycine as a fast inhibitory 
neurotransmitter is more restricted. This probably explains why GABAA receptors constitute a 
group of extremely successful drug targets in the treatment of a wide variety of CNS 
diseases, including anxiety, sleep disorders, and epilepsy, while drugs specifically targeting 
glycine receptors are virtually lacking. However, the spatially more restricted distribution of 
glycinergic inhibition may be advantageous in situations when a more localized enhancement 
of inhibition is sought. Inhibitory GlyRs are particularly relevant for the control of excitability in 
the mammalian spinal cord, brain stem, and a few selected brain areas, such as the 
cerebellum and the retina. At these sites, GlyRs regulate important physiological functions, 
including respiratory rhythms, motor control, muscle tone and sensory as well as pain 
processing. In the hippocampus, RNA-edited high affinity extrasynaptic GlyRs may contribute 
to the pathology of temporal lobe epilepsy. Although specific modulators have not yet been 
identified, GlyRs still possess sites for allosteric modulation by a number of structurally 
diverse molecules, including alcohols, neurosteroids, cannabinoids, tropeines, general 
anaesthetics, certain neurotransmitters and cations. This review summarizes the present 
knowledge about this modulation and the molecular bases of the interactions involved.  
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Introduction 
Strychnine-sensitive GlyRs are pentameric anion channels. Five GlyR subunits have been 
cloned from mammalian tissue and designated α1-α4 and β (Lynch, 2004). Each GlyR 
subunit contains an amino-terminal extracellular domain (ECD), four transmembrane 
domains (TM) and a large intracellular loop (IL) between TM3 and TM4, which configure the 
ligand binding region, the ion channel pore, and sites for intracellular modulation, 
respectively (Baenziger and Corringer, 2011; Lynch, 2004; Sine and Engel, 2006).  
In the adult, most GlyRs are composed of α1 and β subunits probably in a 2(α1)/3β 
stoichiometry (Grudzinska et al., 2005). This GlyR subtype is the main mediator of 
glycinergic inhibition in the adult CNS. Many of these GlyRs colocalize with the postsynaptic 
scaffolding protein gephyrin (Todd et al., 1995; Waldvogel et al., 2010). Early in development 
most GlyRs are α2 homomers, which become replaced around postnatal day 14 by α1β 
heteromers in most CNS areas (Lynch, 2004; Malosio et al., 1991). In a few selected areas, 
such as the retina, α2 persist however into adulthood. Like α1 subunits, α3 subunits are 
mainly found in the adult but their expression is spatially much more restricted. 
Immunohistochemistry and quantitative RT-PCR studies in mice have shown that α3-GlyR 
subunits are predominantly expressed in the superficial laminae of the dorsal horn (Anderson 
et al., 2009; Harvey et al., 2004) and in the respiratory network of the brain stem (Manzke et 
al., 2010). RNA edited α2 and α3-GlyRs may serve a peculiar function as extrasynaptic high 
affinity GlyRs in the hippocampus (Legendre et al., 2009; Meier et al., 2005). The gene 
encoding for the GlyR α4 subunit is a pseudogene in humans due to the presence of a 
premature stop codon (Simon et al., 2004).  
The subunit composition of the ion channel complex and the arrangement of the different 
subunits within this complex determine its pharmacological profile. According to recent data, 
the glycine binding site of α/β heteromeric GlyRs is jointly formed by α and β subunits 
(Grudzinska et al., 2005), while β subunits interact with gephyrin and thereby mediate 
synaptic clustering of GlyRs ((Kim et al., 2006); Pfeiffer et al., 1982; Schmitt et al., 1987). 
Although very few established drugs primarily act through inhibitory GlyRs (Laube et al., 
2002), a number of endogenous messenger molecules and some drugs do modulate GlyRs 
function (Fig. 1). Such compounds include different cations, in particular zinc, cannabinoids, 
neuroactive steroids, tropeines, alcohols, avermectins, butyrolactones and general 
anaesthetics. Most of these molecules do not directly interact with the glycine binding sites 
but rather bind to allosteric sites within the GlyR complex (Fig. 2). It is at present not yet 
established to what extent these interactions contribute to physiology or to drug actions in 
vivo, but their existence clearly establishes a possibility for specific pharmacological 
intervention. The analysis of the molecular bases of the interaction of these compounds with 
GlyRs should hence foster the development of specific GlyR modulators. 
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Possible indications of glycine receptor as a therapeutic target 
Early knowledge about possible roles of glycinergic neurotransmission in physiological 
functions or in diseases has mainly been obtained through pharmacological blockade of 
GlyR with the rodent poison strychnine (for a review see Callister and Graham, 2010). These 
early studies have identified a critical role of GlyRs in the control of muscle tone. Severe 
cramps of the skeletal musculature are the leading symptom of strychnine poisoning. Apart 
from these motor symptoms altered sensory perception such as an increased sensitivity to 
acoustic or tactile stimuli has also frequently been observed. Further evidence in particular 
for the involvement of altered glycinergic inhibition has come from studies in several strains 
of GlyR mutant mice (spasmodic, oscillator, and spastic) which carry mutations in the GlyR 
α1 subunit (spasmodic, oscillator) or in the β subunit (spastic) (Buckwalter et al., 1994; 
Mülhardt et al., 1994; Ryan et al., 1994). These mice are not only exhibit increased muscle 
tone but also show a strong hyperekplexic phenotype, very much reminiscent of human 
startle disease (Koch et al., 1996). In fact, mutations in GlyR subunit genes are frequently 
found in human patients suffering from hyperekplexia/startle disease (Rees et al., 2001).  
There is also evidence that part of the spinal component of inflammatory hyperalgesia (i.e. 
an increased sensitivity to painful stimuli) comes from diminished glycinergic inhibition 
caused by the phosphorylation and inhibition of α3-GlyRs (Ahmadi et al., 2002; Harvey et al., 
2004; Reinold et al., 2005). In the spinal cord, these GlyRs are largely confined to the 
superficial dorsal horn, the main termination area of nociceptive afferent nerve fibers. This 
result fits nicely to early reports showing that exaggerated nociceptive responses can be 
triggered by intrathecal injection of strychnine in rats (Beyer et al., 1985; Yaksh, 1989). Very 
recent evidence indicates that α3-GlyRs also serve an important function in brainstem 
respiratory control where their dephosphorylation through serotonin 5-HT1A receptor 
activation antagonizes opioid-induced respiratory depression (Manzke et al., 2010).  
Although glycinergic innervation is largely confined to the spinal cord, brain stem and 
cerebellum, GlyRs are widely expressed also in the forebrain, where they might become 
activated by ambient glycine. The affinity to glycine of un-edited receptors is normally too low 
for activation by ambient glycine. However, high affinity receptors can be generated through 
cytidine deamination of GlyR transcripts (RNA editing) (Meier et al., 2005). This RNA editing 
gives rise to novel isoforms of α2 and α3-GlyRs carrying a proline to leucine point mutation 
(α2[P192L] and α3[P185L]) (Legendre et al., 2009; Meier et al., 2005). Recent evidence 
suggests that such high affinity extrasynaptic GlyRs contribute to pathological changes in 
temporal lobe epilepsy through the silencing of hippocampal neurons (Eichler et al., 2008). 
In the disease states discussed above, GlyR function is affected through inherited mutations, 
RNA editing, or posttranslational modifications such as phosphorylation. Patients suffering 
from diseases caused by diminished inhibition would probably benefit most from facilitated 
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glycinergic inhibition e.g. through positive allosteric GlyR modulators, while in temporal lobe 
epilepsy an inhibition of GlyRs might be desirable. The following sections address the 
mechanisms of and the molecular sites for such a positive allosteric modulation.  
 
Cannabinoid ligands  
A series of reports published starting in 2005 focused on a possible role of endocannabinoids 
and structurally or functionally related molecules as GlyR modulators. Endocannabinoids are 
endogenous activators of G-protein coupled cannabinoid receptors (CB1 and CB2 receptors) 
(Piomelli, 2003). N-arachidonoyl ethanol amide (AEA, also known as anandamide) was the 
first endocannabinoid discovered, followed by 2-arachidonyl-glycerol (2-AG). Both are lipid 
signalling molecules, structurally related to arachidonic acid. Although many lines of 
evidence indicate that G-protein coupled cannabinoid receptors are the primary targets of 2-
AG and AEA, several studies showed that they interact with additional targets including 
several ion channels (Oz, 2006).  
A direct modulation of GlyR by 2-AG and AEA was first reported in hippocampal neurons 
where both endocannabinoids reduced the amplitude of glycinergic membrane currents and 
altered their rise time, desensitization, and deactivation kinetics in a concentration-dependent 
manner (Lozovaya et al., 2005). This modulation was insensitive to CB1 receptor antagonists 
(SR141716A) and remained intact when the recorded cell was perfused with the ubiquitous 
G protein inhibitor GDP-β-S (Lozovaya et al., 2005). Direct modulation of GlyR by AEA has 
also been found in oocytes expressing recombinant α1-GlyRs (Hejazi et al., 2006). Neither 
SR141716A nor the cannabinoid reuptake inhibitor AM404 prevented the potentiating actions 
of AEA, again indicating that modulation occurred independent of CB1 receptors.  
Following the identification of the two endocannabinoids 2-AG and AEA, additional, 
structurally related endogenous molecules were discovered (Huang et al., 2001). Several of 
these, such as N-arachidonoyl glycine (NA-Gly) and N-arachidonoyl serine (NA-Ser), bind 
CB1 receptors only very weakly, but still modulate GlyRs or other ion channels (Barbara et 
al., 2009; Guo et al., 2008); Yang et al., 2008). Other molecules with agonistic activity at CB1 
or CB2 receptors but structurally unrelated to endocannabinoids also modulate GlyRs. 
Among these are some ingredients of the Cannabis sativa plant (Δ9-tetrahydrocannabinol 
[Δ9-THC], cannabidiol) and several synthetic CB1 and/or CB2 receptor ligands (HU-210, WIN 
55,212-2), which either potentiate or inhibit GlyR currents, sometimes in a subunit-specific 
manner (compare Tab. 1). Although a consistent picture has yet to emerge, these data 
suggest that different molecular determinants exist in the target protein for CB receptor 
activation and GlyR modulation.  
The studies discussed above consistently found that most of the cannabinoid related 
compounds did not directly activate GlyRs but in most cases caused a leftward shift of the 
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glycine concentration response curve. Another important aspect is that native GABAA 
receptors (in rat ventral tegmental area neurons) and recombinant α2β3γ2 GABAA receptors 
expressed in Xenopus laevis oocytes were not modulated by AEA (Hejazi et al., 2006).  
First analyses of possible molecular sites for these allosteric effects were performed by 
Hejazi and coworkers, who found that the sensitivity to AEA was similar in homomeric α1 
and heteromeric α1β-GlyRs indicating that α subunits were sufficient for this modulation 
(Hejazi et al., 2006). They next investigated the influence of a serine to glutamine amino acid 
exchange in α1 at position 267 (S267Q), which was previously shown to abolish the 
potentiation of GlyRs by ethanol and general anaesthetics (Mihic et al., 1997). No change in 
the potentiating action of AEA or Δ9-THC was found in this mutant. However, mutation of the 
serine 267 into an isoleucine (I), which also abolishes GlyR potentiation by ethanol (Mihic et 
al., 1997), prevented potentiation by three molecules structurally-related to Δ9-THC 
(cannabidiol, HU210 and ajulemic acid) (Foadi et al., 2010) suggesting a role of TM2 
residues for the actions of these cannabinoids ligands. More recently, Xiong and coworkers 
demonstrated that potentiation of α1 and α3 GlyRs by Δ9-THC involves a TM3 serine residue 
(S296 on α1 or S307 on α3 GlyRs), which likely contributes to a direct interaction of Δ9-THC 
via hydrogen bonds (Xiong et al., 2011, see also Fig. 2). 
Over the last several years, convincing evidence has accumulated for a direct modulatory 
action of cannabinoid-related compounds on recombinant GlyRs. Data supporting a 
significant contribution of these effects to the in vivo actions of (endo-)cannabinoids were 
however lacking until recently. The report by (Xiong et al., 2011) provides the first evidence 
in support of an in vivo relevance showing that mice lacking α3-GlyRs exhibit a pronounced 
reduction in Δ9-THC-induced analgesia. An important piece of information which is still 
missing in the puzzle is data demonstrating a direct amplification or prolongation of 
glycinergic synaptic currents by (endo-)cannabinoids. 
A second issue which is particularly relevant, when cannabinoid-related molecules are 
considered as lead structures for the development of GlyR modulators, is their lack of 
specificity. Almost all of these molecules also interfere with the function of other ion channels 
(Oz 2006, see also Tab. 2) and many of them also exhibit activity at CB1 or CB2 receptors. 
Again, the report by (Xiong et al., 2011) provides new insights. Introduction of slight chemical 
modifications to the Δ9-THC molecule significantly decreased affinity to CB1 receptors while 
fully retaining activity at GlyRs. Although comprehensive analyses of the molecular 
determinants are definitely still needed, the recent studies indicate that some of the 
cannabinoid-related molecules discussed above may constitute interesting lead compounds 
for the development of GlyR modulators. 
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Ethanol  
Evidence from biochemical and electrophysiological experiments consistently indicates that 
GlyR currents are potentiated by ethanol at concentrations reached in humans after 
moderate ethanol intake. This potentiation originates from a decrease in the glycine EC50 
without a change in maximal currents (Aguayo et al., 1996; Mihic, 1999). Potentiation of 
GlyRs by ethanol is apparently not restricted to certain areas but occurs in neurons 
throughout many parts of the CNS, including spinal cord, hippocampus, hypoglossal nucleus 
and ventral tegmental area (Aguayo et al., 1996; Eggers and Berger, 2004; Jiang and Ye, 
2003). Experiments performed in motoneurons from brain stem and spinal cord slices have 
shown that ethanol increases the amplitude of glycinergic postsynaptic currents suggesting 
that modulation of synaptic GlyRs by ethanol could potentially explain some of the alterations 
caused by ethanol in motor control and respiratory rhythms (Eggers and Berger, 2004; 
Gibson and Berger, 2000; Ziskind-Conhaim et al., 2003).  
Homomeric α1-GlyRs are more sensitive to ethanol than α2-GlyRs especially at 
concentrations below 100 mM (Mascia et al., 1996b; Perkins et al., 2008; Yevenes et al., 
2010). This differential sensitivity correlates well with data from neuronal preparations, in 
which neonatal GlyRs (mostly α2-GlyRs) were less sensitive to ethanol than mature (α1) 
GlyRs (Eggers et al., 2000; Sebe et al., 2003; Tapia and Aguayo, 1998).  
Most of the knowledge about the molecular mechanisms underlying the modulation of GlyRs 
by ethanol originally came from the electrophysiological analysis of a set of chimeric GlyR α1 
/ GABAAρ1 receptors (Mihic et al., 1997). This seminal report identified residues in TM2 
(S267) and TM3 domains (A288) which abolish the ethanol sensitivity of α1-GlyRs. 
Subsequent experiments combining site specific mutagenesis, molecular modelling, and 
covalent binding of alcohol analogues to cysteine mutants consistently determined that TM2 
and TM3 residues jointly shape a water-filled cavity serving as an ethanol-binding pocket 
(Mascia et al., 2000; Ye et al., 1998). Other studies showed that the extracellular loop 2 and 
TM1 residues also play a role in the alcohol modulation of GlyRs, although it is not clear if 
they shape additional binding pockets (Crawford et al., 2008; Lobo et al., 2008). These 
studies clearly demonstrate that both ethanol binding pockets and regulatory elements for 
the ethanol actions are within the TM domains of GlyRs. However, ethanol sensitivity can 
also be effectively controlled by intracellular signalling, possibly suggesting that part of the 
ethanol actions occur indirectly through other ethanol-sensitive proteins. For instance, the 
ethanol-induced potentiation of recombinant and native GlyRs is attenuated by PKC 
inhibitors (Jiang and Ye, 2003; Mascia et al., 1998) and by ct-GRK2, a specific G protein βγ 
sequester peptide (Yevenes et al., 2008). The importance of the Gβγ signalling for the 
alcohol effects on GlyRs also has been demonstrated recently using Gβγ-insensitive α1-
GlyRs, in which the mutation of two intracellular residues (KK385-386) attenuated ethanol 
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effects without altering potentiation induced by general anaesthetics (Yevenes et al., 2008). 
Additionally, a recent report also showed that the differential ethanol sensitivity of α1 and α2-
GlyRs can be better explained by a selective Gβγ modulation rather than by specific TM 
ethanol-binding pockets, which are conserved between these isoforms (Yevenes et al., 
2010). It is still a matter of debate whether direct or indirect actions are more relevant, but 
conceivably both the direct binding of ethanol to the receptor (reviewed in Harris et al., 2008) 
and the indirect modulation of signalling components by ethanol (reviewed in Morrow et al., 
2004) could be equally important and act cooperatively to elicit the final effects on GlyRs. 
The physiological importance of the molecular sites for the ethanol actions in vivo has been 
investigated through genetic approaches in mice carrying the ethanol-insensitive S267Q 
mutation in the α1-GlyR gene. Transgenic expression of S267Q mutated GlyR in mice 
decreased ethanol sensitivity in behavioural assays without inducing apparent behavioural 
changes in the absence of alcohol (Findlay et al., 2002). Although these results support the 
importance of this GlyR site for alcohol actions in vivo, they should be interpreted cautiously 
as a subsequent publication of the same group investigating S267Q point mutated (“knock-
in”) mice has yielded different results. Mice homozygous for the S267 point mutation 
exhibited spontaneous seizures and died three weeks after birth. Heterozygous mice 
survived but still displayed a severe increase in the acoustic startle responses (Findlay et al., 
2003). In vitro experiments demonstrated that the S267Q mutation in α1-GlyR significantly 
reduced the glycine-evoked chloride uptake in spinal cord synaptoneurosomes from 
heterozygous knock-in mice and dramatically disrupted receptor function at the single 
channel level (Findlay et al., 2003).  
 
General anaesthetics 
Many studies on recombinant GlyRs consistently demonstrate that volatile anaesthetics, 
such as isoflurane, enflurane, halothane and sevoflurane potentiate homomeric α1-GlyR 
currents at anaesthetic concentrations (Downie et al., 1996; Krasowski and Harrison, 1999; 
Mascia et al., 1996a; Yamakura et al., 2001). This potentiation is not specific for α1-GlyRs, 
as homomeric α2-GlyRs are also sensitive to isoflurane (Harrison et al., 1993), while α3-
GlyRs remain to be investigated. The anaesthetics studied were unable to activate GlyRs by 
themselves (Downie et al., 1996; Harris et al., 1995; Krasowski and Harrison, 1999), but 
rather caused a leftward shift of the glycine concentration response curve. These effects 
have been reproduced in native receptors. Isoflurane potentiated the glycine-activated 
currents in rat medullary neurons (Downie et al., 1996), and prolonged the decay kinetics and 
increased the frequency of mIPSCs in rat trigeminal nucleus and spinal motoneurons (Cheng 
and Kendig, 2002; Yamashita et al., 2001). Because glycinergic inhibition is largely confined 
to the hindbrain and spinal cord, it is unlikely that the loss of consciousness by volatile 
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anaesthetics is caused via an interaction with GlyRs. However, immobility is an action of 
volatile anaesthetics, which is much more likely related to interactions with GlyR (Rudolph 
and Antkowiak, 2004; Sonner et al., 2003). In line with this idea, isoflurane, enflurane and 
sevoflurane indeed significantly reduced spontaneous action potential firing in neurons 
recorded in organotypic slice cultures of the rat ventral horn (Grasshoff and Antkowiak, 2006 
and 2004). An interaction with GlyRs might also be relevant for sensory processing at the 
spinal dorsal horn level. Extracellular recordings from wide-dynamic range (WDR) neurons in 
intact rats have shown that halothane induced depression in the responses to thermal and 
mechanical noxious stimuli and that this depression was partially reversed by strychnine at 
doses which had no per se effect on WDR neuron firing (Yamauchi et al., 2002). In line with 
these studies, in vivo experiments performed in rats demonstrated that spinal GlyRs are 
important, although not the only, mediators of the isoflurane-induced immobility (Zhang et al., 
2003). 
Intravenous anaesthetics may also have some effect on GlyR function, but these actions are 
more controversial. Propofol displayed significant modulatory activity at GlyR, but the degree 
of this modulation was much less than that of volatile anaesthetics in particular at clinically 
relevant concentrations (Krasowski and Harrison, 1999; Pistis et al., 1997). Homomeric  α1-
GlyRs,  α1/β heteromers, and homomeric α2-GlyRs are similarly sensitive to propofol 
(Mascia et al., 1996b; Pistis et al., 1997), while at least α1-GlyRs appeared to be insensitive 
to etomidate (Mascia et al., 1996a; Pistis et al., 1997). Despite the lack of information on the 
sensitivity of other GlyR subunits or subunit combinations, available evidence suggests that 
GlyRs are unlikely to play a major role in the in vivo effects of the intravenous anaesthetics 
(but see Nguyen et al., 2009). This is also supported by reports, which showed that propofol-
induced immobility was produced exclusively via spinal GABAA receptors (Grasshoff and 
Antkowiak, 2004; Sonner et al., 2003).  
The molecular determinants of GlyR modulation by anaesthetics have been worked out 
hand-in-hand with those of GABAA receptors. In fact, pioneering studies performed in the late 
1990s found sites for volatile anaesthetics within TM domains of GlyRs through the analysis 
of chimeric receptors between the enflurane-sensitive α1-GlyRs and enflurane-insensitive 
ρ1-GABAA receptors (Mihic et al., 1997). This and other studies have consistently shown that 
specific residues within TM2 and TM3 domains of α1-GlyRs potentially shape an intra-
subunit cavity which serves as a general anaesthetic binding pocket and which also acts as 
an acceptor for ethanol and other n-alcohols with longer carbon chains (reviewed in 
Krasowski and Harrison, 1999; Lobo and Harris, 2005). Unfortunately, the knowledge 
regarding the molecular sites for anaesthetics on GlyRs has not yet been translated into 
genetic mouse models. This would be necessary in order to address the role of GlyRs on the 
general anaesthetic actions in vivo.  
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Glutamate 
A recent publication (Liu et al., 2010) provides strong evidence that glutamate, the principal 
fast excitatory neurotransmitter in the CNS, can act as a positive allosteric GlyR modulator. 
This potentiation was seen in spinal neurons in culture and in slices as well as in HEK293 
cells transiently expressing GlyRs. Potentiation of GlyR currents manifested in increased 
single channel open probability and occurred not only by glutamate but also by NMDA, AP5, 
kainate, quisqualate, aspartate and kynurenic acid, while CNQX and NBQX inhibited GlyR 
currents indicating that the pharmacology of this modulation did not match with that of any 
known glutamate receptor. Experiments performed in isolated membrane patches showed 
that this facilitation most likely occurred through a direct binding of glutamate to the GlyR 
channel complex. Homomeric α1-GlyR currents were doubled by glutamate, while 
potentiation of α1/β heteromeric channels was in the rage of about 40-60%, possibly 
suggesting that the putative binding site resides on the GlyR α1 subunit. Potentiation of 
glycinergic inhibition by glutamate may provide an extremely fast feedback mechanism for 
the maintenance of balanced synaptic excitation and inhibition. Although the relevant binding 
sites have not yet been determined and because the findings certainly require independent 
verification, this previously unrecognized modulation may provide an additional possibility for 
therapeutic intervention with GlyRs.  
 
Ivermectin 
Avermectins are a family of macrocyclic lactones derived from the bacterium Streptomyces 
avermitilis and commonly used as anti-parasitic and insecticide agents. They act mainly 
through an allosteric modulation or a direct activation of glutamate-gated chloride channels 
(GluCls) expressed by nematodes and insects (Wolstenholme and Rogers, 2005). Ivermectin 
is one member of this group whose activity on invertebrate GluCls has been characterized in 
detail in recombinant systems (Arena et al., 1992; Cully et al., 1996; Cully et al., 1994; Kane 
et al., 2000). Notably, ivermectin also modulates cationic and anionic ligand-gated ion 
channels including GlyRs in vertebrate (see Table 2). Early electrophysiological studies 
showed that ivermectin influences recombinant homomeric α1 and heteromeric α1β GlyRs at 
submicromolar concentrations (Shan et al., 2001). More recent studies revealed that different 
amino acid substitutions of the TM3 residue A288 differentially affected ivermectin’s action 
on α1 GlyR currents. The mutation A288G increased the ivermectin sensitivity to the 
nanomolar range, whereas the A288F substitution completely abolished its agonistic actions 
(Lynagh and Lynch, 2010), Fig. 2). Equivalent mutations in the corresponding residue in a 
nematode GluCl ion channel showed a similar pattern of effects suggesting that the effects of 
avermectins on these receptors occurs through similar molecular sites (Lynagh and Lynch, 
2010). Since homologous residues have been extensively characterized as binding sites for 
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ethanol and general anaesthetics on GABAA and GlyRs (reviewed in Krasowski and 
Harrison, 1999; Lobo and Harris, 2005; Yamakura et al., 2001), it appears likely that 
avermectins modulate these receptors through similar mechanisms and binding sites. The 
direct activation of GlyRs by ivermectin makes this compound an interesting template to 
design GlyR ligands with agonistic activity. However, ivermectine is not specific for GlyRs 
(see Table 2) and could even inhibit GlyRs in some preparations (Dawson et al., 2000). A 
better understanding of the mechanisms underlying the effects of ivermectin on GlyRs will be 
necessary to design new analogues with improved selectivity. 
 
Neuroactive steroids 
Endogenous neurosteroids are cholesterol metabolites produced locally in the CNS. They 
induce fast changes in neuronal excitability through a direct interaction with ion channels. 
Best established is the facilitating action on GABAA receptors by 5α-pregnan-3α-ol-20-one 
(3α,5α-tetrahydroprogesterone; 3α,5α-THPROG; allopregnanolone) and 5β-pregnan-3α-ol-
20-one (3α,5β-THPROG; pregnanolone), collectively called 3α reduced neurosteroids. These 
neurosteroids neither directly activate nor potentiate GlyRs (Lambert et al., 2001; Pistis et al., 
1997; Weir et al., 2004). 3α,5β-THPROG in fact causes a small but significant inhibition of 
spinal GlyR currents (Fodor et al., 2006; Wu et al., 1997) and 3β-sulphates of pregnenolone 
have been shown to inhibit recombinant GlyRs expressed in oocytes (Maksay et al., 2001).  
By contrast, synthetic neurosteroids such as minaxolone, Org20599 and alphaxalone 
significantly enhanced homomeric α1 GlyR currents in recombinant systems (Ahrens et al., 
2008; Weir et al., 2004). Another recent report has shown that two synthetic pregnanolone 
analogues potentiated homomeric α3 GlyR currents in a voltage-dependent fashion (Jin et 
al., 2009). Although facilitation occurred with EC50 values approximately 10-fold higher than 
those required for GABAA receptors and with generally lower efficacies (Weir et al., 2004), 
experiments on spinal dorsal horn neurons have shown that low micromolar concentrations 
of minaxolone prolong the decay time kinetics of glycinergic mIPSCs in lamina II neurons 
(Mitchell et al., 2007). At 10 μM, minaxolone additionally increased the amplitude, but not the 
frequency of glycinergic mIPSCs. Tonic glycinergic currents found in the same dorsal horn 
neurons were insensitive to minaxolone (Mitchell et al., 2007). The molecular sites involved 
in the modulation elicited by synthetic steroids on different GlyR subtypes are still not 
investigated in depth. The high sensitivity of GABAA receptors to neuroactive steroids 
suggests that their effects are mainly related to GABAergic inhibition.  
 
Tropeines 
Tropeines were originally identified as potent 5-HT3 receptor antagonists. Tropisetron, also 
known as ICS-205,930, is one of the best-known compound of this group. It is used mainly 
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as an antiemetic following chemotherapy due to its ability to target 5-HT3 receptors involved 
in vomiting reflexes. An increasing body of evidence has shown that tropeines also 
allosterically modulate GlyRs of different subunit composition. Pioneering 
electrophysiological recordings in cultured spinal neurons have revealed that two tropeines, 
MDL-72222 and tropisetron, were able to potentiate GlyR chloride currents at nanomolar 
concentrations (Chesnoy-Marchais, 1996). In contrast, higher micromolar concentrations 
caused inhibition. Subsequent studies determined that potentiation only occurred in the 
presence of GlyR agonists, depended on the agonist concentration, and was also present in 
outside-out patches (Chesnoy-Marchais, 1996; Supplisson and Chesnoy-Marchais, 2000; 
Yang et al., 2007). The potentiation elicited by tropisetron remained unaltered in the 
presence of zinc, ethanol or propofol, suggesting different binding sites and mechanisms 
(Chesnoy-Marchais, 1999). Interestingly, tropisetron also displayed subunit-specificity. 
Studies in recombinant GlyRs showed that tropisetron potentiated homomeric α1 but 
inhibited homomeric α2-GlyRs. Furthermore the expression of β subunits significantly 
increased the potentiation sensitivity of α1 and switched α2-GlyR inhibition to potentiation. 
These results suggest that the tropeine potentiating site lies within the α-α or α-β interface 
(Supplisson and Chesnoy-Marchais, 2000). Other studies also found that α2-GlyR was more 
effectively inhibited by tropisetron than α1-GlyR, but in contrast, they did not find any 
potentiation even in the presence of β subunits (Maksay et al., 1999). Despite these 
differences, the electrophysiological data correlated well with binding studies in recombinant 
and native membrane preparations. For example, several tropeines have been shown to 
inhibit 3[H]strychnine binding to GlyRs with high nanomolar affinity. In addition they increase 
the glycine potency to displace 3[H]strychnine, suggesting direct effects on glycine binding 
sites (Maksay, 1998; Maksay et al., 2004). In general terms, structure-activity analysis 
suggests that the tropeine ring itself, the tropeine nitrogen, an aromatic ring and a carbonyl 
group are necessary for binding and functional potentiation (Chesnoy-Marchais et al., 2000; 
Maksay, 1998; Maksay et al., 2004). The tropeine ring, on the other hand, appears to be a 
primary requirement for functional inhibition (Maksay et al., 2009; Yang et al., 2007). 
Recently, several studies addressed the location of the tropeine binding sites on GlyRs. In 
agreement with studies performed in 5-HT3 receptors (Joshi et al., 2006; Yan and White, 
2005), tropeines appear to bind to cavities within the extracellular domain located close to 
the ligand binding sites. Using recombinant GlyRs, Yang et al. (2007) showed that mutations 
to N102 in the α1, but not in the β subunit (N125), abolished tropisetron inhibition without 
affecting the potentiation. Subsequent work performed with a structurally related tropeine 
(3α-(3’-methoxy-benzoyloxy) nortropane, MBN) determined that other amino acid 
substitutions close to the agonist-binding domain of α1-GlyRs also alter the MBN inhibition or 
potentiation of GlyRs (see Fig. 2, Maksay et al., 2009). In addition, homology models and 
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molecular docking simulations also suggest that the bi-phasic modulation elicited by 
tropeines on GlyRs is likely to involve different docking modes in adjacent binding sites within 
the agonist-binding region (Maksay et al., 2009). 
The high affinity binding and the remarkable sensitivity of GlyRs to tropeines makes this 
group of compounds one of the most promising candidates for the development of specific 
drugs targeting GlyRs. Despite the existence of some interesting differences between the 
chemical determinants required for tropeine binding to GlyRs and 5-HT3 receptors, most 
tropeines still bind and modulate 5-HT3 receptors with high affinity (Maksay et al., 2004). In 
addition, the bi-phasic nature of tropeine-GlyR modulation and the significant overlap 
between the requirements for potentiation and inhibition is also an important impediment to 
their use as enhances of GlyR function. A better understanding of the mechanisms 
underlying the potentiation of GlyR subtypes by tropeines will hopefully lead to new tropeine 
agents lacking glycinergic inhibition and 5-HT3 receptor binding. 
 
Zinc 
The interaction of GlyRs with the cation zinc is probably at present the best characterized 
form of allosteric modulation of GlyR. Previous research has not only consistently 
established the molecular sites involved, but work in point mutated mice has also firmly 
established a physiological role of this modulation. Zinc modulates GlyRs in a bi-phasic 
manner. Potentiation dominates at low (< 10 µM) concentrations while inhibition occurs at 
higher concentrations (>10 µM) (Bloomenthal et al., 1994; Doi et al., 1999; Laube et al., 
2000). This bi-directional modulation involves different molecular sites. Potentiation is due to 
an increase in the affinity of GlyRs to glycine, while inhibition occurs through reduced 
efficacy. Amino acids involved in the potentiation by zinc are D80, E192, E194 (Laube et al., 
2000; Lynch et al., 1998), while inhibition involves H107, H109, T112, and T133 (all positions 
refer to α1-GlyR) (Harvey et al., 1999; Laube et al., 2000; Miller et al., 2005). The different 
glycine receptor isoforms differ in their susceptibility to modulation by glycine. Zinc inhibits 
α2-GlyR and α3-GlyR to a lesser degree than α1-GlyR. This difference is apparently due to 
the substitution of amino acid H107 in α1-GlyR by an asparagine residue in the 
corresponding positions in α2 and α3-GlyR. Generation of a point mutated mouse carrying a 
D80A substitution, which largely ablates the potentiating effects of zinc without changing 
glycine sensitivity, expression level, or receptor trafficking to the synapse, revealed a 
physiological function of this modulatory site (and of zinc itself) in spinal cord neuronal 
circuits (Hirzel et al., 2006). Homozygous D80A point mutated mice exhibit a progressive 
hyperekplexia-like phenotype starting about at day P12, when α1-GlyRs replace embryonic 
α2-GlyRs. Whether these zinc modulatory sites are suitable for therapeutic targeting is 
however at present not known.  
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Conclusions  
Pharmacological modulation of glycinergic inhibition could represent a novel therapeutic 
strategy against a variety of diseases involving altered synaptic inhibition primarily in the 
spinal cord and brain stem but possibly also at supraspinal sites. Several endogenous 
molecules including neurotransmitters and neuromodulators, and exogenous substances 
such as anaesthetics and alcohols have been identified that modulate GlyR function. As 
most pathologies linked to GlyR dysfunction involve diminished GlyR activity, positive 
allosteric modulation appears desirable in the majority of cases. Most currently available 
GlyR modulators are rather promiscuous and by no means specific for GlyRs (compare Tab. 
2). These compounds are therefore not suitable for a therapeutic approach targeted 
specifically towards GlyRs. However, for several of them, direct modulation through allosteric 
sites is either firmly established or very likely. Yet in most cases (with the exception of zinc) 
the sites responsible are not yet firmly established. The existence of putative distinct sites for 
allosteric modulation on GlyRs however indicates future possibilities for a specific modulation 
of GlyR subtypes by novel synthetic ligands. This perhaps optimistic view is supported by the 
recent report which showed that an unbiased high throughput screening approach led to the 
identification of several highly specific GlyR modulator peptides (Tipps et al., 2010). A 
comprehensive mapping of the molecular sites and mechanism involved will certainly 
facilitate the identification and development of small molecules specifically targeting GlyRs. 
In the absence of high-resolution structures for GlyRs (and hence also of structural data of 
these receptors with bound allosteric modulators or agonists), our knowledge is restricted to 
what can be inferred from functional studies using recombinant mutant receptors. 
Alternatively, advances might also come from the analysis of structurally related channels. 
High-resolution X-ray structures have recently been obtained from bacterial pentameric 
ligand-gated ion channel (reviewed recently by Baenziger and Corringer, 2011). For the 
bacterial proton-activated ion channel GLIC crystal structures have even been obtained with 
a general anaesthetics bound (Nury et al., 2011). Such data will hopefully foster future 
structure-function studies on GlyRs, for example through improved homology modelling and 
molecular dynamic simulations. Through these and other new approaches, the discovery and 
development of new synthetic drugs targeting GlyRs with improved specificity and efficacy 
appears to be not too far fetched.  
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Table 1. Cannabinoid ligand effects on native and recombinant GlyRs 
Compound Native GlyRs (EC50 or concentration range examined) Comments Reference 
AEA ↓ 0.1 – 1 µM neonatal rat hippocampal pyramidal neurons1 100 µM glycine 
(≈ EC50) Lozovaya et al., 2005 2-AG 
↓ 1 µM 
neonatal rat hippocampal pyramidal neurons1
WIN 55,212-2 Little effect on amplitude, but τdes and τon decreased (0.1 – 10 µM) 
AEA ↑ (230 nM) acutely dissociated VTA neurons 5 µM glycine  Hejazi et al., 2006 Δ9- THC ↑ (115 nM) acutely dissociated VTA neurons
Δ9- THC ↑ (0.03-1 μM) cultured spinal neurons 10 µM glycine ≈ EC2) Xiong et al., 2011 
meth-AEA No effect on the amplitude or kinetics of glycinergic mIPSCs from spinal cord dorsal horn slices
5 µM 
meth-AEA Anderson et al., 2009 
 
 Recombinant GlyRs(EC50 or concentration range examined)   
 α1 α1/β α2 α3   
Δ9-THC ↑ (86nM) ↑(73nM) - - 3-5 µM glycine Hejazi et al., 2006
Δ9-THC (0.03-50 μM)2 - ↑(0.03-50 μM)2 ↑(0.03-50 μM)2 
 ≈ EC2  
(subunit-
dependent) 
Xiong et al., 2011 
AEA ↑ (320nM) ↑ (320nM) - - 3-5 µM glycine Hejazi et al., 2006
AEA ↑ (38 nM) ↑ no effect no effect ≈ EC10  
(subunit-
dependent) 
Yang et al., 2008 HU-210 ↑ (270nM) ↑ ↑ (90 nM) ↑ (50 nM) WIN 55,212-2 no effect no effect ↓ (0.22µM) ↓ (86 nM) 
N-arachidonyl-glycine complex action2 complex action2 ↑(3.03µM) ↑(1.32µM) 
Ajulemic acid ↑(9.7 µM)3 ↑(12.4µM)3 - - 10 µM glycine Ahrens et al., 2009b
Cannabidiol ↑(12.3 µM)3 ↑(18.1 µM)3 - - 10 µM glycine Ahrens et al., 2009a
 
 1 Qualitatively similar effects were obtained in cerebellar Purkinje neurons.   
 2 EC50 values were not reported. The sensitivity to Δ9-THC was α1=α3>α2 
 3 Complex actions with initial potentiation and subsequent inhibition 
 4 Direct activation was observed at 10-20 fold higher concentrations. 
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Group Representative ligands GlyR (relative potency1) Additional targets References 
Volatile 
anaesthetics 
Isoflurane 
Enflurane 
↑↑ GABAA-R 
Voltage-gated Ca2+ channels 
NMDA-R 
2P-domain K+ channels 
Yamakura et al., 2001 
Franks, 2008 
 
Intravenous 
anaesthetics 
 
Propofol 
 
↑↑ GABAA-R 
L-type Ca2+ channels 
11β-hydroxylase 
Yamakura et al., 2001 
Rudolph and Antkowiak, 2004 
Franks, 2008 
n-alcohols Ethanol ↑ GABAA-R 
NMDA-R 
GIRK channels 
Aguayo et al., 2002 
Harris et al., 2008 
 
Avermectins Ivermectin ↑↑** nAch-Rs 
GABAA-R 
P2X4-R 
Krusek and Zemkova, 1994 
Krause et al., 1998 
Silberberg et al., 2007 
Jelinkova et al., 2008 
Adelsberger et al., 2000 
Tropeines Tropisetron ↑↑↑ / ↓↓3 5HT3-R Thompson and Lummis, 2007 
Cannabinoid 
ligands 
Anandamide 
THC 
↑↑↑ / ↓↓ CB-R 
TRPV1 
nAch-Rs / 5HT3-R 
Piomelli, 2003 
Oz, 2006 
Bivalent cations Zn2+ ↑↑ / ↓↓3 GABAA-R 
NMDA-R 
TrkB-R 
Smart et al., 2004 
Mony et al., 2009 
Sensi et al., 2009 
Glutamatergic 
ligands 
AP5 
NMDA 
↑↑ NMDA-R Dingledine et al., 1999 
 
Table 2. GlyR positive allosteric modulators and their additional targets 
 
 Potentiation or inhibition ranges: ↑↑↑ or ↓↓↓, nM; ↑↑ or ↓↓, μM; ↑ or ↓, mM 
 1 Mainly from functional studies using electrophysiology (see text) 
 2 Direct activator  
 3 Bi-phasic modulation, inhibition at >10-50 μM 
 
 
 
Figure legends 
 
Figure 1. Allosteric modulation of GlyR subtypes 
The scheme summarizes the interactions between several groups of allosteric modulators with 
different GlyR subtypes. Examples of some representative chemical structures for each group of 
compounds are shown.  
 
 
Figure 2. Molecular sites for positive allosteric modulators of GlyR function 
Critical residues are shown for several allosteric modulators that exert positive effects on GlyR 
function. The amino acid positions described were identified in functional experiments performed 
on the α1-GlyR mutants. The molecular sites involved in the effects elicited by neuroactive 
steroids, some cannabinoid ligands (i.e. endocannabinoids and synthetic cannabinoids) and 
glutamate receptor ligands remain to be defined. Data are from Mascia et al. (1996b), Michic et al. 
(1997), Laube et al. (2000), Lynch et al. (1998), Maksay et al. (2009), Lynagh and Lynch (2010), 
Xinog et al. (2011) and Yevenes et al. (2008). 
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